Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MYL-1501D product using manufacture process V · 1 trial · 1 indication
Change in HbA1c from baseline
| Arm | Type | Description |
|---|---|---|
| MYL-1501D (Process V Product) | ACTIVE_COMPARATOR | MYL-1501D (Process V Product) |
| MYL-1501D (Process VI Product) | ACTIVE_COMPARATOR | MYL-1501D (Process VI Product) |
| Name | Type | Description |
|---|---|---|
| MYL-1501D product using manufacture process V | DRUG | MYL-1501D product using manufacture process V |
| MYL-1501D product using manufacture process VI | DRUG | MYL-1501D product using manufacture process VI |
Inclusion Criteria: 1. Written and signed informed consent needs to be provided by subjects or their legal representatives before starting any protocol-specific procedures. 2. Male and female subjects between the ages of 18 to 65 years, both ages inclusive. 3. Subjects with an established diagnosis...
MYL-1501D product using manufacture process V is an investigational small molecule being developed for the treatment of Type 1 Diabetes Mellitus. It is currently in Phase 3 clinical development and has not been approved by regulatory authorities.
MYL-1501D product using manufacture process V is being developed by Viatris Inc., a company traded on the stock exchange under the ticker symbol VTRS. The drug is currently in Phase 3 clinical trials for Type 1 Diabetes Mellitus.
MYL-1501D product using manufacture process V is in Phase 3 clinical development. It is an investigational drug for Type 1 Diabetes Mellitus and has not yet been approved by regulatory agencies. One Phase 3 trial has been completed.
MYL-1501D product using manufacture process V has one completed Phase 3 clinical trial, identified as NCT03376789, titled "Mylan Insulin Glargine Study." This randomized, double-blind, active-controlled trial enrolled 219 participants with Type 1 Diabetes Mellitus in the United States.
MYL-1501D product using manufacture process V is not FDA approved. It is an investigational drug currently in Phase 3 clinical development for Type 1 Diabetes Mellitus. The drug has completed one Phase 3 trial but has not yet received regulatory approval.